Swedish Orphan Biovitrum returns ITP asset rights to Symphogen
This article was originally published in Scrip
Swedish Orphan Biovitrum has returned full development rights to its immune thrombocytopenic purpura (ITP) treatment candidate to co-developer Symphogen as it prioritises its late-stage development pipeline.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.